Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Journal of Virology|June 1, 1993
Cross-reactive lysis of human targets infected with prototypic and clinical human immunodeficiency virus type 1 (HIV-1) strains by murine anti-HIV-1 IIIB env-specific cytotoxic T lymphocytesS Chada, C E DeJesus, K Townsend, et al.
HIV Medicine|October 24, 2012
Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trialC Orkin, E DeJesus, H Khanlou, et al.
Experimental Hematology|November 20, 2010
Transient neutropenia after granulocyte-colony stimulating factor administration is associated with neutrophil accumulation in pulmonary vasculatureCatherine E DeJesus, Jackson Egen, Mark Metzger, et al.
Plos One|November 6, 2018
Pyronaridine exerts potent cytotoxicity on human breast and hematological cancer cells through induction of apoptosisPaulina J Villanueva, Alberto Martinez, Sarah T Baca, et al.
Oncogene|December 22, 1999
Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytesM Nesbit, H K Nesbit, J Bennett, et al.
HIV Medicine|July 16, 2015
The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavirD A Wohl, L Bhatti, C B Small, et al.
Cell Biology and Toxicology|March 3, 2019
A new pyridazinone exhibits potent cytotoxicity on human cancer cells via apoptosis and poly-ubiquitinated protein accumulationDenisse A Gutierrez, Rebecca E DeJesus, Lisett Contreras, et al.
Human Gene Therapy|July 1, 1994
Cytotoxic T lymphocyte and antibody responses generated in rhesus monkeys immunized with retroviral vector-transduced fibroblasts expressing human immunodeficiency virus type-1 IIIB ENV/REV proteinsL S Laube, M Burrascano, C E Dejesus, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 31, 2013
SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimenR Campo, E DeJesus, U F Bredeek, et al.
Neoplasia (New York, N.Y.)|November 28, 2016
Activation of WNT/β-Catenin Signaling Enhances Pancreatic Cancer Development and the Malignant Potential Via Up-regulation of Cyr61Makoto Sano, David R Driscoll, Wilfredo E DeJesus-Monge, et al.
Pageof 4